Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Therapy plus Intense ADT for Metastatic Prostate Cancer
NCT06992232Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Event-free Survival at 2 years. Started Aug 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06992232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992232.